T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced
HER2-Negative Breast Cancer A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy